Expert Interviews

Surya Bhatt, MD, MSPH, Reports the Pivotal Phase 3 Findings for Dupilumab as Add-On Treatment for COPD
May 31, 2024

The dual interleukin-4, 13 inhibitor reduced COPD exacerbation rates by as much as 34% for individuals with COPD with type 2 inflammation, Bhatt explains.

Primary Care Needs Training on Menopausal Issues, Treatment Options, says Women's Midlife Health Expert
May 30, 2024

Primary care clinicians are essential to maximizing evidence-based midlife care for women, according to Professor of Obstetrics & Gynecology JoAnn Pinkerton, MD.

Elinzanetant Outcomes from the OASIS 1 and 2 Phase 3 Trials: A Read Out with Lead Investigator JoAnn Pinkerton, MD
May 29, 2024

The novel dual neurokinin-1,3 antagonist reduced VMS after just 1 week of treatment, Pinkerton said, and improved sleep and quality of life, as well. Hear more.

Key Takeaways and Clinical Pearls for the Utilization of Teplizumab
May 28, 2024

A panel of experts in the management of diabetes share their key takeaways and clinical pearls for the utilization of teplizumab for the delay of onset of type 1 diabetes.

Navigating Teplizumab: Dosing, Infusion Process, and Patient Experience in Delaying Late Onset Diabetes
May 28, 2024

Kent Stoneking Pharm D, CDECS and Marianne Briggs, DNP, FNP-C share their experiences with the dosing regimen and infusion process for teplizumab. This segment offers an in-depth look at the 14-day course of treatment, providing insights into the patient experience and what individuals can expect during this crucial intervention period.

Empowering Progress: Teplizumab's FDA Approval and Mechanism of Action in Delaying T1D Progression
May 28, 2024

In this discussion, a panel of diabetes management experts examines the groundbreaking potential of teplizumab, the first FDA-approved therapy of its kind, in delaying the onset of T1D stage progression. They discuss its unique mechanism of action and explore its pivotal role in early intervention strategies.

Type 1 Diabetes Antibody Screening: Keys for Early Intervention and Risk Determination
May 28, 2024

Dr Jennifer D. Goldman and Marianne Briggs, DNP, FNP-C explore the critical role of antibodies in determining T1D progression and emphasize the importance of regular screening. In this segment learn about the four main antibodies pivotal in T1D screening and stage progression.

Strategies to Prolong T1D Stage Progression: Impact of Diabetes Ketoacidosis and Potential for Extending Insulin Independence
May 28, 2024

Jennifer D. Goldman, RPh, PharmD, CDCES, BC-ADM, FCCP, discusses the stages of T1D progression. She emphasizes the risks of delaying intervention in stage 2 T1D, including heightened DKA risk and severe complications, along with potential treatment efficacy reduction and poorer long-term glycemic control.

Navigating the Burden of Diabetes: Screening Recommendations and Insights from Real-Life Experiences
May 28, 2024

Kent Stoneking Pharm D, CDECS, shares his personal T1D story and underscores the critical importance of early diagnosis and intervention for this condition. Following his story, Marianne Briggs, DNP, FNP-C, provides invaluable suggestions for identifying individuals at risk for T1D through effective screening methods.

Deciphering Diabetes Onset: The Crucial Role of B Cells and Diagnosis Considerations
May 28, 2024

Kashif Latif, MD defines diabetes, shedding light on the pivotal role of B cells. He introduces the concept of diabetes stages and emphasizes the critical importance of early intervention to prevent complications.